Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 48-61

  Bellacosa, Alfonso ^a,i   Godwin, Andrew K ^b   Peri, Suraj ^c   Devarajan, Karthik ^c   Caretti, Elena ^f   Vanderveer, Lisa ^b   Bove, Betsy ^b   Slater, Carolyn ^b   Zhou, Yan ^c   Daly, Mary ^e   Howard, Sharon ^d   Campbell, Kerry S ^d   Nicolas, Emmanuelle ^d   Yeung, Anthony T ^f   Clapper, Margie L ^e   Crowell, James A ^g   Lynch, Henry T ^h   Ross, Eric ^c   Kopelovich, Levy ^g   Knudson, Alfred G ^f  

^a Epigenetics and Progenitor Cells and Human Genetics Programs   (United States)

^b Ovarian Cancer Program   (United States)

^c Department of Biostatistics ^*  (United States)

^d Division of Medical Science   (United States)

^e Cancer Prevention and Control Program   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; MAMMAGLOBIN; MESSENGER RNA; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; MUTANT; MUTATION; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; BREAST; DATA MINING; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; OVARY; PHYSIOLOGY;

BREAST; DATA MINING; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77649208363     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0078     Document Type: Article

References (47)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Armitage P, Doll R. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 1954;8:1-12.
3. Erickson LC. The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition. Semin Cancer Biol 1991;2:257-65.
4. Danes BS. Increased in vitro tetraploidy: tissue specific within the heritable colorectal cancer syndromes with polyposis coli. Cancer 1978;41:2330-4.
5. Kopelovich L. Phenotypic markers in human skin fibroblasts as possible diagnostic indices of hereditary adenomatosis of the colon and rectum. Cancer 1977;40:2534-41.
6. Kopelovich L. Heritable colorectal cancer and cancer genes: systemic expressions. Mol Carcinog 1993;8:3-6.
7. Yeung AT, Patel BB, Li XM, et al. One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. Cancer Res 2008;68:7579-86.
8. Kopelovich L. Genetic predisposition to cancer in man: in vitro studies. Int Rev Cytol 1982;77:63-88.
9. Stoyanova R, Clapper ML, Bellacosa A, et al. Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther 2004;3:1313-21.
10. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266:120-2.
11. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
12. Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996;12:333-7.
13. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
14. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
15. Caretti E, Devarajan K, Coudry R, et al. Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection. J Cell Biochem 2008;103:556-63.
16. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
17. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
18. Jain N, Thatte J, Braciale T, Ley K, O'Connell M, Lee JK. Local-pooled-error test for identifying differentially expressed genes with a small number of replicated microarrays. Bioinformatics 2003;19:1945-51.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 1995;57:289-300.
20. Pascual-Montano A, Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Marqui RD. bioNMF: a versatile tool for non-negative matrix factorization in biology. BMC Bioinformatics 2006;7:366-74.
21. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50.
22. Behbod F, Xian W, Shaw CA, Hilsenbeck SG, Tsimelzon A, Rosen JM. Transcriptional profiling of mammary gland side population cells. Stem Cells 2006;24:1065-74.
23. Ince TA, Richardson AL, Bell GW, et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007;12:160-70.
24. Cho RW, Wang X, Diehn M, et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008;26:364-71.
25. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
26. Bernstein JL, Godbold JH, Raptis G, et al. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005;11:6528-35.
27. Ntoulia M, Stathopoulou A, Ignatiadis M, et al. Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006;39:879-87.
28. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005; 96:183-90.
29. Li X, Cao X, Zhang W, Feng Y. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci 2007;98:1592-6.
30. Lo SH, Lo TB. Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Res 2002;62:4217-21.
31. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 2000;15:343-56.
32. Khan N, Cromer CJ, Campa M, Patz EF, Jr. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 2004;101:379-84.
33. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005;5:3790-7.
34. Wenham RM, Calingaert B, Ali S, et al. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig 2003;10:381-7.
35. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118:1367-79.
36. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005;65:3735-44.
37. Gupta RA, Tejada LV, Tong BJ, et al. Cyclooxygenase-1 is over-expressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003;63:906-11.
38. Iwaya K, Ogawa H, Mukai Y, Iwamatsu A, Mukai K. Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. Cancer Sci 2003;94:864-70.
39. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000.
40. Harper JW, Elledge SJ. The DNA damage response: ten years after. Mol Cell 2007;28:739-45.
41. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
42. Vilenchik MM, Knudson AG. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A 2003;100:12871-6.
43. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000;16:69-74.
44. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004;95:866-71.
45. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 2008; 105:1680-5.
46. Burga LN, Tung NM, Troyan SL, et al. Altered proliferation and differentiation properties of primary mammary epithelial cells from BRCA1 mutation carriers. Cancer Res 2009;69:1273-8.
47. Claij N, Te Riele H. Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level. Oncogene 2002;21: 2873-9.